Analysts' Actions: JNJ FNFG WLL CA VRTX

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

CA ( CA) was downgraded from buy to neutral at Mizuho. $25 price target. CEO could change the product development process, which might cause near-term disruptions, Mizuho said.

F5 Networks ( FFIV) was downgraded to hold at TheStreet Ratings.

First Niagara ( FNFG) was upgraded to outperform at KBW. $10.50 price target. New CEO could prove to be an inflection point for the company, Keefe, Bruyette & Woods said.

Johnson & Johnson ( JNJ) was downgraded to neutral from overweight at J.P. Morgan. $83 price target. Valuation call.

Juniper Networks ( JNPR) was upgraded at Argus to buy from hold. $22 price target. Earnings recovery is finally underway, Argus said.

L-3 Communications ( LLL) was downgraded at J.P. Morgan to underweight from neutral. Company is most at risk from sequestration cuts, J.P. Morgan said.

Vail Resorts ( MTN) was downgraded at Credit Suisse to neutral from outperform. $64 price target. Valuation call, as the stock is up 44% over the past year, Credit Suisse said.

Northrop Grumman ( NOC) was upgraded at J.P. Morgan to equal-weight from underweight. Valuation call, J.P. Morgan said.

Public Service ( PEG) was downgraded at Argus to hold from buy. Valuation call, as the stock is approaching the previous $35 price target, Argus said.

RDA Microelectronics ( RDA) was downgraded to hold at TheStreet Ratings.

Vertex Pharmaceuticals ( VRTX) was initiated with a hold rating at Canaccord. Valuation call, based on a $55 price target.

Whiting Petroleum ( WLL) was upgraded to overweight at J.P. Morgan. Valuation call, given the company's better outlook, J.P. Morgan said.

STOCK COMMENTS/EPS CHANGES

Apple ( AAPL) estimates were increased at Canaccord Genuity through 2014. Company is seeing higher iPhone 4 and 4S sales, and new products should continue to drive demand. Buy rating and $600 price target.

AstraZeneca ( AZN) estimates were cut at Leerink Swann through 2014. Cautious feedback for Fostamatinib lowers the chance for FDA approval, Leerink Swann said.

Daimler ( DDAIF) price target and estimates were reduced at UBS. First-quarter guidance was worse than expected on weak markets (Germany) and wholesale sales, driving a reduction in earnings estimates, said UBS. The price target goes to $70.22.

Hanesbrands ( HBI) price target and estimates were increased at Citigroup. The price target was increased to $54 after the company initiated a dividend which will attract new investors, said Citigroup. Earnings estimates for 2013 were increased given a better-than-expected first quarter result, Citigroup added.

If you liked this article you might like

Crazy Weak U.S. Dollar Will Make These 10 Companies Huge Winners

Cramer: Goldman's Downgrade Of J&J Is 'Questionable'

Johnson & Johnson Stock Sinks, Goldman Downgrades to 'Sell'

The Best Companies for Women

Ridiculously Weak U.S. Dollar Will Make These 10 Companies Huge Winners